Literature DB >> 35315685

Impact of Acquired Broad-Spectrum β-Lactamases on Susceptibility to Cefiderocol and Newly Developed β-Lactam/β-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa.

Laurent Poirel1,2,3, Jose-Manuel Ortiz de la Rosa1, Mustafa Sadek1,4, Patrice Nordmann1,2,3,5.   

Abstract

The ability of broad-spectrum β-lactamases to reduce the susceptibility to ceftazidime-avibactam (CZA), ceftolozane-tazobactam (C/T), imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam (AZA), and cefiderocol (FDC) was evaluated both in Pseudomonas aeruginosa and in Escherichia coli using isogenic backgrounds. Although metallo-β-lactamases conferred resistance in most cases, except for AZA, several clavulanic-acid-inhibited extended-spectrum β-lactamases (PER, BEL, SHV) had a significant impact on the susceptibility to CZA, C/T, and FDC.

Entities:  

Keywords:  Pseudomonas aeruginosa; cefiderocol; susceptibility testing; β-lactamase

Mesh：

Substances：

Year:  2022        PMID： 35315685      PMCID： PMC9017383          DOI： 10.1128/aac.00039-22

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.938


  12 in total

1.  ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa.

Authors:  José-Manuel Ortiz de la Rosa; Patrice Nordmann; Laurent Poirel
Journal:  J Antimicrob Chemother       Date:  2019-07-01       Impact factor: 5.790

2.  Prevalence of extended-spectrum beta-lactamases in South America.

Authors:  M V Villegas; J N Kattan; M G Quinteros; J M Casellas
Journal:  Clin Microbiol Infect       Date:  2008-01       Impact factor: 8.067

3.  Stability of cefiderocol against clinically significant broad-spectrum oxacillinases.

Authors:  Laurent Poirel; Nicolas Kieffer; Patrice Nordmann
Journal:  Int J Antimicrob Agents       Date:  2018-11-08       Impact factor: 5.283

Review 4.  Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.

Authors:  George G Zhanel; Alyssa R Golden; Sheryl Zelenitsky; Karyn Wiebe; Courtney K Lawrence; Heather J Adam; Temilolu Idowu; Ronald Domalaon; Frank Schweizer; Michael A Zhanel; Philippe R S Lagacé-Wiens; Andrew J Walkty; Ayman Noreddin; Joseph P Lynch Iii; James A Karlowsky
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

5.  Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens.

Authors:  J Dobias; V Dénervaud-Tendon; L Poirel; P Nordmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-07-26       Impact factor: 3.267

6.  Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants.

Authors:  Laurent Poirel; Mustafa Sadek; Ayda Kusaksizoglu; Patrice Nordmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-01-28       Impact factor: 3.267

Review 7.  Avibactam Pharmacokinetic/Pharmacodynamic Targets.

Authors:  Wright W Nichols; Paul Newell; Ian A Critchley; Todd Riccobene; Shampa Das
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

8.  Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC β-lactamase mutants and the inoculum effect.

Authors:  Claire Amaris Hobson; Aurélie Cointe; Hervé Jacquier; Alaksh Choudhury; Mélanie Magnan; Céline Courroux; Olivier Tenaillon; Stéphane Bonacorsi; André Birgy
Journal:  Clin Microbiol Infect       Date:  2021-04-26       Impact factor: 8.067

9.  Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections.

Authors:  Yohei Doi
Journal:  Clin Infect Dis       Date:  2019-11-13       Impact factor: 9.079

10.  Contribution of PER-Type and NDM-Type β-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii.

Authors:  Laurent Poirel; Mustafa Sadek; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2021-07-12       Impact factor: 5.191
View more
  4 in total

1.  NDM-35-Producing ST167 Escherichia coli Highly Resistant to β-Lactams Including Cefiderocol.

Authors:  Laurent Poirel; José Manuel Ortiz de la Rosa; Zeynep Sakaoglu; Ayda Kusaksizoglu; Mustafa Sadek; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2022-07-11       Impact factor: 5.938

Review 2.  Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance.

Authors:  Stamatis Karakonstantis; Maria Rousaki; Evangelos I Kritsotakis
Journal:  Antibiotics (Basel)       Date:  2022-05-27

3.  Evolution of β-lactamase-mediated cefiderocol resistance.

Authors:  Christopher Fröhlich; Vidar Sørum; Nobuhiko Tokuriki; Pål Jarle Johnsen; Ørjan Samuelsen
Journal:  J Antimicrob Chemother       Date:  2022-08-25       Impact factor: 5.758

4.  Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa.

Authors:  María José Contreras-Gómez; José R W Martinez; Lina Rivas; Roberto Riquelme-Neira; Juan A Ugalde; Aniela Wozniak; Patricia García; José M Munita; Jorge Olivares-Pacheco; Manuel Alcalde-Rico
Journal:  Front Pharmacol       Date:  2022-10-03       Impact factor: 5.988
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.